A patient with basal cell carcinoma on the temple — one of the face's highest-risk zones — returns after surgery with recurrence. Dermatology Times has published the first in a case series examining exactly this scenario: the surgery-refractory patient whose tumor comes back in a site where tissue is scarce and margins matter.

The temple sits in the so-called H-zone of the face, where BCC carries elevated recurrence risk and subclinical extension runs further than the naked eye suggests. That anatomy is the whole problem. When a tumor recurs there after surgical treatment, the clinician faces a narrowing set of options and a patient who has already been through one procedure.

Why the temple is unforgiving

Location drives strategy in BCC management. Temple lesions sit near critical structures, and recurrent tumors in this area behave less predictably than primary ones. Recurrence after surgery typically signals aggressive histology, incomplete clearance, or both — and each of those possibilities pushes the next therapeutic decision in a different direction.

The case format matters here. Rather than a review of treatment modalities in the abstract, Dermatology Times presents a single patient trajectory, letting readers follow the assessment logic step by step: what the prior surgery tells you, what to examine first, and which factors — histologic subtype, margin status, patient factors — should steer the choice between re-excision, Mohs micrographic surgery, radiation, or systemic therapy.

What does this change for practitioners?

For clinicians who manage BCC routinely, the value is in the refractory framing. Most temple BCCs resolve cleanly with appropriate surgery. The ones that don't demand a structured reassessment, not a reflexive repeat of what already failed. Case-based guidance on that reassessment — published in a peer-adjacent clinical outlet like Dermatology Times — gives practitioners a template for their own difficult patients.

The "Case 1" label suggests more cases are coming. If the series maintains this focus on treatment-resistant presentations, it could become a useful running reference for the situations where standard protocols run out of road.

Derm Field will monitor the series as subsequent cases publish.